Related Experiment Videos
[Pathological hyperprolactinemia II. course and diagnostic and therapeutic problems].
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|October 7, 1982
Summary
Bromoergocriptine is the primary treatment for prolactinomas, effectively managing most cases. Surgery is reserved for specific complex situations, including drug-resistant tumors or rapid pregnancy-related growth.
Area of Science:
- Endocrinology
- Neurosurgery
Background:
- Prolactinomas, pituitary tumors producing prolactin, often grow slowly.
- Mixed adenomas can present with acromegaly or Cushing syndrome, potentially treatable with bromoergocriptine.
Purpose of the Study:
- To outline the current management strategies for prolactinomas.
- To define the roles of medical and surgical interventions.
Main Methods:
- Review of clinical management principles for prolactinomas.
- Discussion of indications for bromoergocriptine therapy and surgical intervention.
Main Results:
- Bromoergocriptine is the cornerstone of prolactinoma management.
- Surgery is indicated for specific cases like large, encapsulated, or drug-resistant tumors, and severe pregnancy-related exacerbations.
Conclusions:
- Medical management with bromoergocriptine is highly effective for most prolactinomas.
- Surgical intervention remains crucial for select, complex cases and when medical therapy fails.